Showing results (271-280 of 304) with videos related to

Sort By:
Pageof 31
Cancers|August 28, 2025
Clinical, Histopathological, Dermoscopic Features, and BRAF, NRAS, and Cell Cycle Genes' Mutation Status in Cutaneous MelanomaMaria A Pizzichetta, Jerry Polesel, Maria C Sini, et al.
Cancers|April 23, 2022
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus ReviewMattia Garutti, Gaia Griguolo, Andrea Botticelli, et al.
Eclinicalmedicine|April 30, 2024
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trialsEva Blondeaux, Wanling Xie, Luca Carmisciano, et al.
Tumori|March 11, 2011
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM)Stefania Gori, Massimo Di Maio, Carmine Pinto, et al.
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.
Breast Cancer Research : BCR|August 8, 2020
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancerLaura Biganzoli, Saverio Cinieri, Rossana Berardi, et al.
ESMO Open|August 28, 2020
Oncological care organisation during COVID-19 outbreakConcetta Elisa Onesti, Hope S Rugo, Daniele Generali, et al.
The Lancet. Oncology|September 20, 2021
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, et al.
NPJ Breast Cancer|February 5, 2025
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapyLuca Mastrantoni, Giovanna Garufi, Giulia Giordano, et al.
Cancer Treatment Reviews|August 29, 2024
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical reviewAlberto Zambelli, Laura Cortesi, Mariangela Gaudio, et al.
Pageof 31